<DOC>
	<DOCNO>NCT00941031</DOCNO>
	<brief_summary>The purpose study determine whether , patient moderate severe plaque-type psoriasis , AIN457 administer subcutaneously reduce severity psoriasis symptom extent patient 's body area affect disease ( compare placebo ) .</brief_summary>
	<brief_title>AIN457 Regimen Finding Study Patients With Moderate Severe Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Men woman least 18 year age time consent Chronic plaquetype psoriasis diagnose least 6 month time randomization At time randomization , moderate severe psoriasis define : PASI score 12 great IGA score 3 great Body Surface Area ( BSA ) affect plaquetype psoriasis 10 % great At screen randomization , chronic plaquetype psoriasis consider inadequately control : topical treatment and/or phototherapy and/or previous systemic therapy Patients meeting follow criterion exclude entry study : Forms psoriasis chronic plaquetype ( e.g. , pustular , erythrodermic guttate psoriasis ) screen randomization Druginduced psoriasis ( i.e . new onset current exacerbation betablockers , calcium channel inhibitor lithium ) randomization Ongoing use prohibit psoriasis treatment ( e.g. , topical systemic corticosteroid , UV therapy ) randomization . Washout period detail study protocol adhere Ongoing use prohibit treatment randomization . Washout period detail study protocol adhere . All prior concomitant medication must stable dose least four week study drug administration Known immunosuppression ( e.g. , AIDS ) screen / randomization History evidence active tuberculosis screening . All patient test tuberculosis status use blood test ( QuantiFERON®TB Gold InTube ) . Patients evidence latent tuberculosis may enter trial sufficient treatment initiate accord local regulation . Active systemic infection ( common cold ) two week randomization ( e.g. , hepatitis ) At screening , history symptom malignancy organ system ( history basal cell carcinoma / three squamous cell carcinoma skin , successful treatment perform , sign recurrence ; actinic keratoses , present screening , treat accord standard therapy randomization ) , treat untreated , within past 5 year , regardless whether evidence local recurrence metastasis History congestive heart failure ( NYHA functional classification ≥III ) screen / randomization History severe hypersensitivity human humanize biological agent ( antibody soluble receptor ) screen / randomization Any severe , progressive uncontrolled medical condition randomization judgment investigator prevents patient participate study Pregnant nursing ( lactate ) woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Moderate severe chronic plaque-type psoriasis</keyword>
	<keyword>AIN457</keyword>
	<keyword>dermatology</keyword>
</DOC>